Joyce O'Shaughnessy

7PUBLICATIONS
71CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 01, 2024
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.

Aditya Bardia, Javier Cortés, François-Clément Bidard

|Jul 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira

|May 29, 2024
A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer.

Kerigo Ndirangu, Rachel Goldgrub, Vanita Tongbram

|Dec 07, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Peter Schmid, Nicholas C Turner, Carlos H Barrios

|Nov 08, 2023
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7.

Aleix Prat, Nadia Solovieff, Fabrice André

|Jul 07, 2023
Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.

Antoinette R Tan, Joyce O'Shaughnessy, Subing Cao

Pageof 2

Frequent Collaborators

2 joint publications

Ruffo Freitas-Junior

2 joint publications

Antoinette R Tan

2 joint publications

Steven J Isakoff

2 joint publications

Phillipe Aftimos